To determine whether knocking down EIF4A2 affects oxaliplatin sensitivity in vivo, CRC cells with shEIF4A2–1 or shCTRL were subcutaneously injected into nude mice and treated with oxaliplatin. This evidence concerns the gene EIF4A2 and colorectal carcinoma.